Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts

Florence Coussy (1) , Marion Lavigne (2) , Leanne de Koning (3) , Rania El Botty (4) , Fariba Nemati (4) , Adnan Naguez (4) , Guillaume Bataillon (2) , Berengère Ouine (3) , Ahmed Dahmani (4) , Elodie Montaudon (4) , Pierre Painsec (4) , Sophie Chateau-Joubert (5) , Fuhrmann Laetitia (2) , Thibaut Larcher (6, 7) , Sophie Vacher (8) , Walid Chemlali (8) , Adrien Briaux (8) , Samia Melaabi (8) , Anne Vincent Salomon (2) , Jean Marc Guinebretiere (2) , Ivan Bieche (8, 9) , Elisabetta Marangoni (4)

1 Unit of Pharmacogenomics, Department of Genetics,Laboratory of Preclinical Investigation, Department of Translational Research, Department of Medical Oncology
2 Department of Biopathology
3 Translational Research Department, RPPA Platform
4 Laboratory of Preclinical Investigation, Department of Translational Research
5 Biopôle Alfort
6 PAnTher - Physiopathologie Animale et bioThérapie du muscle et du système nerveux
7 APEX - Expertise en Anatomie Pathologique
8 Unit of Pharmacogenomics, Department of Genetics
9 IC UM3 (UMR 8104 / U1016) - Institut Cochin

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts

Domaines: Sciences du Vivant [q-bio]

Florence Coussy, Marion Lavigne, Leanne de Koning, Rania El Botty, Fariba Nemati, et al.. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Theranostics, 2020, 10 (4), pp.1531-1543. ⟨10.7150/thno.36182⟩. ⟨hal-02509541⟩